You are here

Discrepancies between Canadian cancer research funding and site-specific cancer burden

TitleDiscrepancies between Canadian cancer research funding and site-specific cancer burden
Year of Publication2018
AuthorsCoronado, A.. C., Finley C.., Badovinac K.., Han J.., Niu J.., and Rahal R..
JournalCurrent Oncology
Volume25
Pages338 - 341
Keywordsincidence, mortality, research investment
Abstract

Background Cancer research is essential in evaluating the safety and effectiveness of emerging cancer treatments, which in turn can lead to ground-breaking advancements in cancer care. Given limited research funding, allocating resources in alignment with societal burden is essential. However, evidence shows that such alignment does not typically occur. The objective of the present study was to provide an updated overview of site-specific cancer research investment in Canada and to explore potential discrepancies between the site-specific burden and the level of research investment. Methods The 10 cancer sites with the highest mortality in 2015-which included brain, female breast, colorectal, leukemia, lung, non-Hodgkin lymphoma, ovary, pancreas, prostate, and uterus-were selected for the analysis. Information about site-specific research investment and cancer burden (raw incidence and mortality) was obtained from the Canadian Cancer Research Survey and Statistics Canada's cansim (the Canadian Socio-Economic Information Management System) respectively. The ratio of site-specific research investment to site-specific burden was used as an indicator of overfunding (ratio > 1) or underfunding (ratio

URLhttp://current-oncology.com/index.php/oncology/article/view/4230
DOI10.3747/co.25.4230
Document URLhttp://current-oncology.com/index.php/oncology/article/view/4230/2887